Xiao-Jian Zhou
Overview
Explore the profile of Xiao-Jian Zhou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
87
Citations
617
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Deng X, Song C, Gu W, Wang Y, Feng L, Zhou X, et al.
Bioresour Bioprocess
. 2024 Jul;
11(1):64.
PMID: 38954282
Regioselective and enantioselective hydroxylation of propargylic C-H bonds are useful reactions but often lack appropriate catalysts. Here a green and efficient asymmetric hydroxylation of primary and secondary C-H bonds at...
2.
Zhou X, Horga A, Puri A, Winchester L, Montrond M, Pietropaolo K, et al.
J Antimicrob Chemother
. 2024 May;
79(6):1423-1431.
PMID: 38708557
Background: Bemnifosbuvir (AT-527) is a novel oral guanosine nucleotide antiviral drug for the treatment of persons with COVID-19. Direct assessment of drug disposition in the lungs, via bronchoalveolar lavage, is...
3.
Zhou X, Lickliter J, Montrond M, Ishak L, Pietropaolo K, James D, et al.
Antimicrob Agents Chemother
. 2024 Mar;
68(5):e0161523.
PMID: 38526047
AT-752 is a novel guanosine nucleotide prodrug inhibitor of the dengue virus (DENV) polymerase with sub-micromolar, pan-serotype antiviral activity. This phase 1, double-blind, placebo-controlled, first-in-human study evaluated the safety, tolerability,...
4.
Zhou X, Good S, Pietropaolo K, Huang Q, Moussa A, Hammond J, et al.
Expert Opin Investig Drugs
. 2024 Jan;
33(1):9-17.
PMID: 38265202
Introduction: Chronic hepatitis C virus (HCV) persists as a public health concern worldwide. Consequently, optimizing HCV therapy remains an important objective. While current therapies are generally highly effective, advanced antiviral...
5.
Horga A, Saenz R, Yilmaz G, Simon-Campos A, Pietropaolo K, Stubbings W, et al.
Future Virol
. 2023 Nov;
PMID: 37928891
This phase III study assessed the efficacy/safety/antiviral activity/pharmacokinetics of bemnifosbuvir, a novel, oral nucleotide analog to treat COVID-19. Outpatient adults/adolescents with mild-to-moderate COVID-19 were randomized 2:1 to bemnifosbuvir/placebo. Time to...
6.
Boffito M, Dolan E, Singh K, Holmes W, Wildum S, Horga A, et al.
Microbiol Spectr
. 2023 Jun;
11(4):e0007723.
PMID: 37338393
Bemnifosbuvir is an oral antiviral drug with a dual mechanism of action targeting viral RNA polymerase, with activity against SARS-CoV-2. We conducted a phase 2, double-blind study evaluating the antiviral...
7.
Liu Y, Zhou X, Li Y
J Obstet Gynaecol
. 2022 Aug;
42(7):2813-2817.
PMID: 35980725
A total of 179 normal full-term pregnant women and their newborns were randomly selected. Umbilical venous blood was extracted after the delivery, and the serum level of 25(OH)D3 was measured....
8.
Zhou X, Zhao J, Lai Y, You Y, Wang Z, Yuan W
Chirality
. 2022 May;
34(7):1019-1034.
PMID: 35521642
A readily available chiral cyclohexanediamine-derived bifunctional tertiary amine-squaramide catalyst is more effective for the asymmetric dearomative 1,3-dipolar cycloaddition of 2-nitrobenzofurans and N-2,2,2-trifluoroethylisatin ketimines. A range of structurally diverse spiro-fused polyheterocyclic...
9.
Zhou X, Qin Z, Lu J, Hong J
Chin Med J (Engl)
. 2021 Nov;
134(24):2954-2961.
PMID: 34784306
Background: Despite the recommendation of inhaled corticosteroids (ICSs) plus long-acting beta 2-agonist (LABA) and leukotriene receptor antagonist (LTRA) or ICS/LTRA as stepwise approaches in asthmatic children, there is a lack...
10.
Good S, Westover J, Jung K, Zhou X, Moussa A, La Colla P, et al.
Antimicrob Agents Chemother
. 2021 Feb;
65(4).
PMID: 33558299
The impact of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of COVID-19, is global and unprecedented. Although remdesivir has recently been approved by the FDA to treat SARS-CoV-2...